Patents Examined by Nelson B Moseley, II
-
Patent number: 12221626Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.Type: GrantFiled: August 13, 2021Date of Patent: February 11, 2025Assignee: Immatics Biotechnologies GmbHInventors: Andrea Mahr, Toni Weinschenk, Oliver Schoor, Jens Fritsche, Harpreet Singh, Colette Song
-
Patent number: 12222356Abstract: This invention relates to methods for predicting a prognosis of a patient with cancer in need of an anti-cancer treatment comprising measuring a cytokine score from a sample obtained from the patient. In some embodiments, the subject is administered an anti-cancer treatment, e.g., an anti-PD-1 antibody, following the cytokine score measurement. In some embodiments, the cancer is lung cancer.Type: GrantFiled: November 19, 2021Date of Patent: February 11, 2025Assignee: Bristol-Myers Squibb CompanyInventor: Benedetto Farsaci
-
Patent number: 12214004Abstract: The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for preventing or treating cancers, comprising the same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention has effects of inhibiting the proliferation of cancer cells, decreasing the mobility of cancer cells, inhibiting the neoangiogenesis, and increasing the anticancer immune response as well as reducing the expression of inflammatory factors, thereby having effects of preventing or treating cancers or inflammatory diseases. In addition, when used in combination with an anticancer chemotherapeutic agent or an anticancer immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. In addition, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for preventing or treating cancers, comprising the same.Type: GrantFiled: November 12, 2020Date of Patent: February 4, 2025Assignee: Genome And CompanyInventors: Hansoo Park, Shinyoung Park, Eun Ju Lee, Jae-Sung Yeon, Hye Hee Jeon, Wonduck Kim, Joo-Yeon Chung, Areum Jeong, Youn Kyung Houh, Jinyoung Sohn, Yun Yeon Kim, Sang Gyun Kim, Suro Lee
-
Patent number: 12215163Abstract: Provided herein are antibodies that specifically bind to CD25. Also provided herein are methods of making the antibodies described, and methods of use thereof. For example, the CD25 antibodies may be used therapeutically to treat cancer or autoimmune diseases, and in certain aspects: disrupt the trimerization of the beta, gamma, and alpha (CD25) chains of the IL-2 receptor, bind to a different epitope than to which Daclizumab or Baciliximab bind, exhibit a higher affinity of binding to CD25 at a pH lower than 7.4, when compared to the affinity of binding to CD25 at a pH of 7.4, and/or exhibit a higher affinity of binding to CD25 at a pH of about 6.5.Type: GrantFiled: May 13, 2021Date of Patent: February 4, 2025Assignee: iBio, Inc.Inventors: Phung Tu Gip, Bing Li, Matthew P. Greving, Matt Lundberg, Mohan Srinivasan
-
Patent number: 12209137Abstract: The present invention provides an antigen binding protein specifically binding to a CT45 antigenic peptide that is in a complex with a major histocompatibility complex (MHC) protein, wherein the CT45 antigenic peptide comprises or consists of the amino acid sequence of SEQ ID NO: 138 (KIFEMLEGV) and wherein the antigen binding protein comprises a first polypeptide comprising a variable domain VA comprising complementarity determining regions CDRa1, CDRa2 and CDRa3 and a second polypeptide comprising a variable domain VB comprising CDRb1, CDRb2 and CDRb3. Also provided are nucleic acids encoding the antigen binding proteins, vectors comprising the nucleic acids, recombinant cells expressing the antigen binding proteins and pharmaceutical compositions comprising the antigen binding proteins. The invention further provides the antigen binding proteins for use in medicine and a method of producing the antigen binding protein.Type: GrantFiled: July 27, 2022Date of Patent: January 28, 2025Assignee: Emmatics Biotechmiogieg GmbHInventors: Sara Yousef, Fabian Brunk, Andreas Moritz, Sebastian Bunk, Claudia Wagner, Dominik Maurer, Felix Unverdorben
-
Patent number: 12195547Abstract: The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas). More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder (e.g., B cell proliferative disorder) by administering a combination of an anti-CD20/anti-CD3 bispecific antibody and an anti-CD79b antibody drug conjugate.Type: GrantFiled: April 29, 2022Date of Patent: January 14, 2025Assignee: Hoffmann-La Roche Inc.Inventors: Katharina Lechner, Thomas Francis Moore, Martin Weisser, Natalie Dimier, David John Carlile, Nassim Djebli, Peter Nabil Morcos, Linda Maria Lundberg
-
Patent number: 12194095Abstract: The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.Type: GrantFiled: December 8, 2021Date of Patent: January 14, 2025Assignee: Incyte CorporationInventors: Jan Endell, Mark Winderlich, Rainer Boxhammer
-
Patent number: 12187798Abstract: The present invention relates to specific binding members which bind to lymphocyte-activation gene 3 (LAG-3). The specific binding members preferably comprise a LAG-3 antigen-binding site which may be located in two or more structural loops of a CH3 domain of the specific binding member. The specific binding members of the invention find application, for example, in cancer therapy.Type: GrantFiled: November 23, 2021Date of Patent: January 7, 2025Assignee: INVOX PHARMA LIMITEDInventors: Mihriban Tuna, Francisca Wollerton van Horck, Katy Louise Everett, Miguel Gaspar, Matthew Kraman, Katarzyna Kmiecik, Natalie Fosh
-
Patent number: 12187800Abstract: The present invention encompasses antibodies and fragments thereof that bind to an extracellular domain of B7H3, and uses thereof.Type: GrantFiled: November 22, 2018Date of Patent: January 7, 2025Assignees: SUZHOU KANOVA BIOPHARMACEUTICAL CO., LTD., BEIJING KANOVA BIOPHARMACEUTICALS CO. LTD.Inventors: Li Guo, Yuan Dou, Tiantian Sun, Jiaming Li, Xiaoxu Qi, Chen Dong
-
Patent number: 12180297Abstract: The present disclosure provides polypeptide constructs that act as agonists of immune cell function when exposed to sufficient levels of ATP to cause their assembly into dimers or higher level complexes (e.g., trimers, tetramers, etc.). The complexes of the constructs are capable of stimulating immune cells (e.g., cytotoxic CD8+ T cell and/or NK cells) that function to promote anti-tumor immune responses. The constructs may be employed as anticancer agents/therapeutics for the treatment of solid tumors that have elevated levels of ATP.Type: GrantFiled: March 1, 2024Date of Patent: December 31, 2024Assignee: Crosslink Therapeutics Inc.Inventors: Rodolfo J. Chaparro, Ronald D. Seidel, III
-
Patent number: 12178847Abstract: The present invention relates to, inter alia, compositions and methods, including chimeric proteins that find use in the treatment of disease, such as immunotherapies for cancer and autoimmunity. In part, the invention provides, in various embodiments, fusions of extracellular domains of transmembrane proteins that can have stimulatory or inhibitory effects.Type: GrantFiled: March 9, 2020Date of Patent: December 31, 2024Assignee: Kopfkino IP, LLCInventors: Taylor Schreiber, George Fromm, Suresh De Silva, Neal Schilling
-
Patent number: 12180521Abstract: Compositions and methods relating to paraoxonase fusion polypeptides are disclosed. In some aspects, the fusions are bispecific molecules that include a first biologically active polypeptide linked amino-terminal to a biologically active paraoxonase, wherein the first biologically active polypeptide is a DNase, an RNase, a SOD1, a CTLA-4 extracellular domain, a CD40 extracellular domain, or a polypeptide that specifically binds and neutralizes an inflammatory cytokine. Bispecific fusions may further include a second biologically active polypeptide (e.g., a dimerizing or FcRn-binding domain) linked carboxyl-terminal to the first biologically active polypeptide and amino-terminal to the paraoxonase. In other aspects, a fusion polypeptide includes a biologically active paraoxonase linked carboxyl-terminal or amino-terminal to a dimerizing or FcRn-binding domain. Also disclosed are dimeric proteins comprising first and second paraoxonase fusion polypeptides as disclosed herein.Type: GrantFiled: February 17, 2022Date of Patent: December 31, 2024Assignee: Theripion, Inc.Inventors: Jeffrey A. Ledbetter, Martha S. Hayden-Ledbetter
-
Patent number: 12180552Abstract: The present invention relates to antibody-drug conjugates (ADCs) wherein a linker drug is site-specifically conjugated to an antibody through an engineered cysteine, and their use as a medicament, notably for the treatment of human solid tumours and haematological malignancies, in particular breast cancer, gastric cancer, colorectal cancer, urothelial cancer, ovarian cancer, uterine cancer, lung cancer, mesothelioma, liver cancer, pancreatic cancer, prostate cancer, and leukaemia.Type: GrantFiled: August 23, 2021Date of Patent: December 31, 2024Assignee: Byondis B.V.Inventors: Gerardus Joseph Andreas Ariaans, Rudy Gerardus Elisabeth Coumans
-
Patent number: 12173064Abstract: The present invention relates to antibodies specifically binding PD-1, TIM-3 or PD-1 and TIM-3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.Type: GrantFiled: November 6, 2020Date of Patent: December 24, 2024Assignee: Janssen Biotech, Inc.Inventors: Raluca Verona, Gordon Powers, Nina Chi Sabins, Nikki A. DeAngelis, Sandra Santulli-Marotto, Karla R. Wiehagen, Sheng-Jiun Wu, Catherine Ferrante, Enrique Zudaire Ubani
-
Patent number: 12162940Abstract: Antigen binding polypeptide specifically binding to ?/? T cell receptor (TCR)/cluster of differentiation 3 (CD3) complex. Nucleic acid containing a sequence encoding for the antigen binding polypeptide or a vector containing the nucleic acid. Recombinant host cells containing the antigen binding polypeptide, and pharmaceutical compositions containing the antigen binding polypeptide, the nucleic acid, the vector, and/or the host cell. Use of the antigen binding polypeptide, the nucleic acid, the vector, the host cell, or the pharmaceutical composition in medicine, in particular for use in the diagnosis, prevention, and/or treatment of a proliferative disease. Methods for improving or maintaining the binding and/or improving the stability of the antigen binding polypeptides. Methods for detecting, determining or enriching T cells expressing the ?/? TCR/CD3 complex.Type: GrantFiled: May 4, 2022Date of Patent: December 10, 2024Assignee: Immatics Biotechnologies GmbHInventors: Sebastian Bunk, Felix Unverdorben, Martin Hofmann
-
Patent number: 12161692Abstract: The present invention relates to SAP-Fc fusion proteins comprising one or more amino acid substitution, for example, C226S and/or C229S. In some aspects, the fusion protein comprises a structure represented by the following formula, from N-terminus to C-terminus, SAP-Fc1-L1-Fc2, wherein Fc1 is a first Fc domain sequence comprising hinge-CH2-CH3, L1 is a linker, and Fc2 is a second Fc domain sequence comprising hinge-CH2-CH3. The present invention also relates to methods of treating amyloid related diseases by administering said SAP-Fc fusion proteins to a subject in need thereof.Type: GrantFiled: November 1, 2021Date of Patent: December 10, 2024Assignees: Attralus, Inc., UNIVERSITY OF TENNESSEE RESSEARCH FOUNDATIONInventors: Jaume Pons, Jonathan S. Wall
-
Patent number: 12157073Abstract: In certain embodiments, the invention provides a method of purifying a protein of interest from a mixture which comprises the protein of interest and one or more contaminants.Type: GrantFiled: May 22, 2020Date of Patent: December 3, 2024Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Jue Wang, Neil E. Jaffe, Krina Patel
-
Patent number: 12152077Abstract: The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.Type: GrantFiled: May 12, 2023Date of Patent: November 26, 2024Assignees: INSTITUT CURIE, MNEMO THERAPEUTICS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)Inventors: Sebastian Amigorena, Marianne Burbage, Alexandre Houy, Marc-Henri Stern, Joshua Waterfall, Benjamin Sadacca, Antonela Merlotti Ippolito, Yago Arribas De Sandoval
-
Patent number: 12150960Abstract: The present disclosure relates to compositions and methods for enhancing T cell response and/or CAR cell expansion and/or maintenance in vivo and/or in vitro. For example, a method of enhancing T cell-based therapy comprises administering genetically modified T cells comprising a first chimeric antigen receptor (CAR) and a second CAR, wherein a binding domain of the first CAR binds a first antigen, and a binding domain of the second CAR binds a second antigen. The first antigen is different from the second antigen. In embodiments, the first CAR binds a surface molecule or antigen of a white blood cell.Type: GrantFiled: December 1, 2020Date of Patent: November 26, 2024Assignees: Innovative Cellular Therapeutics Holdings, Ltd., Innovative Cellular Therapeutics, Inc.Inventors: Lei Xiao, Zhiyuan Cao, Chengfei Pu, He Sun
-
Patent number: 12152070Abstract: The present invention provides a PTX3 monoclonal antibody or antibody Fab fragment thereof and use thereof. The aforementioned monoclonal antibody or antibody Fab fragment thereof specifically inhibit or slow down the binding of PTX3 to the PTX3 receptor, and may be used for a kit and method for detecting PTX3, and a pharmaceutical composition which inhibits or slows down diseases or symptoms associated with PTX3 and PTX3 receptor binding, and a use thereof.Type: GrantFiled: September 13, 2019Date of Patent: November 26, 2024Assignee: Ohealth Biopharmaceutical (Suzhou) Co., Ltd.Inventors: Ju-Ming Wang, I-Chen Lee, Yu-Wei Hsiao, Jhih-Ying Chi, Jyun-yi Du, Hsin-Yin Liang, Chao-chun Cheng, Chiung-Yuan Ko, Feng-Wei Chen, Jhih-Yun Liu